What is Applied Molecular Transport Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Applied Molecular Transport's Sloan Ratio %
For the Biotechnology subindustry, Applied Molecular Transport's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied Molecular Transport's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Applied Molecular Transport's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Applied Molecular Transport's Sloan Ratio % falls into.
Applied Molecular Transport Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Applied Molecular Transport's Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was -22.599 (Dec. 2022 ) + -27.917 (Mar. 2023 ) + -17.333 (Jun. 2023 ) + -6.937 (Sep. 2023 ) = $-74.79 Mil.
Applied Molecular Transport's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 was -14.816 (Dec. 2022 ) + -19.298 (Mar. 2023 ) + -21.523 (Jun. 2023 ) + -4.399 (Sep. 2023 ) = $-60.04 Mil.
Applied Molecular Transport's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 was -0.006 (Dec. 2022 ) + -0.007 (Mar. 2023 ) + 1.471 (Jun. 2023 ) + 0.045 (Sep. 2023 ) = $1.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Molecular Transport (NAS:AMTI) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2023, Applied Molecular Transport has a Sloan Ratio of -81.20%, indicating earnings are more likely to be made up of accruals.
Applied Molecular Transport Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Applied Molecular Transport's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Applied Molecular Transport (Applied Molecular Transport) Business Description
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMTI has been successfully added to your 